Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Giorgia, Ciurlia"'
Autor:
Piotr Kuna, Joanna Jerzynska, Matteo Martini, Andrea Vele, Irene Barneschi, Fabrizia Mariotti, George Georges, Giorgia Ciurlia
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 4, Pp n/a-n/a (2022)
Abstract The single‐inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been e
Externí odkaz:
https://doaj.org/article/5246b48956d840d282147d9fa8e3e673
Autor:
Carlo Dani, Gyula Talosi, Annalisa Piccinno, Virginia Maria Ginocchio, Gyorgy Balla, Anna Lavizzari, Zbynek Stranak, Eloisa Gitto, Stefano Martinelli, Richard Plavka, Barbara Krolak-Olejnik, Gianluca Lista, Francesca Spedicato, Giorgia Ciurlia, Debora Santoro, David Sweet
Publikováno v:
The Journal of pediatrics. 246
To investigate the efficacy and safety of nebulized poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure compared with nasal continuous positive airway pressure alone in premature infants
Publikováno v:
Singh, D, Ciurlia, G, Piccinno, A, Muraro, A, Bocchi, M & Scuri, M 2017, ' Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients : A single-dose, randomised, placebo-controlled crossover study ', Pulmonary pharmacology & therapeutics, vol. 42, pp. 43-51 . https://doi.org/10.1016/j.pupt.2016.12.004
INTRODUCTION: An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some years for the management of asthma and chronic obstructive
Autor:
Gianluigi Poli, G. Georges, Fabrizia Mariotti, Giorgia Ciurlia, L. Girardello, Z. Luo, P. Guller
Publikováno v:
C32. COPD: TRANSLATIONAL AND MECHANISTIC STUDIES.
Autor:
Mirco Govoni, Paolo Malvezzi, Valérie Garrigue, Arnaud Del Bello, Yannick Le Meur, Giorgia Ciurlia, Silvia Geraci, Elisabeth Cassuto, Lionel Rostaing, Nassim Kamar, Gianluigi Poli, Gabriele Nicolini, Marie Essig, Christophe Mariat, Giovanni Piotti
Publikováno v:
Advances in Therapy
Advances in Therapy, 2019, 36 (2), pp.462-477. ⟨10.1007/s12325-018-0855-1⟩
Advances in Therapy, Springer Verlag (Germany), 2019, 36 (2), pp.462-477. ⟨10.1007/s12325-018-0855-1⟩
Advances in Therapy, Springer Verlag (Germany), 2018
Advances in Therapy, 2019, 36 (2), pp.462-477. ⟨10.1007/s12325-018-0855-1⟩
Advances in Therapy, Springer Verlag (Germany), 2019, 36 (2), pp.462-477. ⟨10.1007/s12325-018-0855-1⟩
Advances in Therapy, Springer Verlag (Germany), 2018
Introduction Different prolonged-release formulations of tacrolimus are available. To date, the pharmacokinetic (PK) profile of LCP-tacrolimus (LCPT; Envarsus®) has not been compared with PR-Tac (Advagraf®) in de novo kidney transplant recipients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a5b8c0be84d8f53df7a5f0c265121b
https://doi.org/10.1007/s12325-018-0855-1
https://doi.org/10.1007/s12325-018-0855-1
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives CHF 5993 is an extrafine ‘triple therapy’ combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF), and the inhaled corticosteroid beclometaso
Autor:
Francesco Sergio, Daniela Acerbi, Li Juel Mortensen, Dave Singh, Nasim Samandari, Maja Deleuran, Erik Nilsson, Bo L. Chawes, Eskil Kreiner-Møller, Mirco Govoni, Gianluigi Poli, Anna Dossing, Nanna L. Skytt, Annalisa Piccinno, Giorgia Ciurlia, Porntiva Poorisrisak, Anne Marie Bisgaard, Hans Bisgaard, Nadja Hawwa Vissing
Publikováno v:
Respiratory Medicine. 108:1108-1116
Summary Aim Prescription of inhaled corticosteroids to children with asthma is recommended at half the nominal dose of adults in order to reduce the risk of systemic side effects. However, there is a lack of pharmacokinetic trials supporting such dos
Autor:
Maja Deleuran, Hans Bisgaard, Bo L. Chawes, Annalisa Piccinno, Gianluigi Poli, Nadja Hawwa Vissing, Anna Dossing, Giorgia Ciurlia, Eskil Kreiner-Møller, Erik Nilson, Amalie Bisgaard, Nanna L. Skytt, Nasim Samandari, Francesco Sergio, Li Juel Mortensen, Porntiva Poorisrisak, Daniela Acerbi
Publikováno v:
British Journal of Clinical Pharmacology. 75:1081-1088
Aim The fixed combination of beclomethasone (BDP) and formoterol pressurized metered dose inhaler (pMDI) (Foster®, Chiesi Farmaceutici) is being developed in the lower strength (BDP/formoterol: 50/6 μg) to provide an appropriate dosage for children
Publikováno v:
5.1 Airway Pharmacology and Treatment.
We evaluated the cardiovascular effects of extrafine BDP/FF (100/6 µg/ actuation) at two dose levels delivered as dry powder (DPI) via NEXThaler ® or an approved pMDI (Foster ® ) in COPD patients. Methods: Forty-nine subjects with a post-bronchodi
Autor:
Bo L K, Chawes, Annalisa, Piccinno, Eskil, Kreiner-Møller, Nadja H, Vissing, Porntiva, Poorisrisak, Li, Mortensen, Erik, Nilson, Amalie, Bisgaard, Anna, Dossing, Maja, Deleuran, Nanna L, Skytt, Nasim, Samandari, Francesco, Sergio, Giorgia, Ciurlia, Gianluigi, Poli, Daniela, Acerbi, Hans, Bisgaard
Publikováno v:
British journal of clinical pharmacology. 75(4)
The fixed combination of beclomethasone (BDP) and formoterol pressurized metered dose inhaler (pMDI) (Foster®, Chiesi Farmaceutici) is being developed in the lower strength (BDP/formoterol: 50/6 μg) to provide an appropriate dosage for children wit